A study of NBI-74788 for the treatment of classic, 21-hydroxylase deficiency congenital adrenal hyperplasia (CAH)
Phase of Trial: Phase II
Latest Information Update: 01 Nov 2017
At a glance
- Drugs NBI 74788 (Primary)
- Indications Congenital adrenal hyperplasia
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- 01 Nov 2017 According to a Neurocrine Biosciences media release, the company expects to initiate this study in November 2017.
- 09 Aug 2017 New trial record
- 03 Aug 2017 According to a Neurocrine Biosciences media release, the company plans to initiate this study in the third quarter of 2017.